SINGLE DOSE AMPHETAMINE EFFECTS IN SCHIZOPHRENIA

这项研究旨在确定哪些慢性精神分裂症患者 可能是慢性多巴胺激动剂特别合适的候选药物 治疗。 使用交叉随机顺序设计，精神分裂症患者被给予 单剂量口服安非他明。患者受到保护，免受可能的伤害 正在进行的氟哌啶醇治疗加剧了他们的精神障碍。我们 假设精神分裂症的缺陷症状可能是一个反映 皮质多巴胺能衰竭的症状。因为皮质多巴胺受体 D_1亚型和中脑边缘多巴胺能神经元多为D_2亚型 亚型，我们假设苯丙胺，一种非特异性多巴胺 给服用相对特定的D2的人服用的非导向性激动剂 阻断剂氟哌啶醇可增强D_1功能。 与安非他明日相比，21名患者中有6名患者的情况有所好转。 到了安慰剂日。这六个人都有共同的大脑室对脑 与无反应的人相比，眨眼的比率和更大的提高 一群人。长期给药的研究正在进行中。

This study is designed to identify those chronic schizophrenic patients who might be especially appropriate candidates for chronic dopamine agonist treatment. Using a crossover random order design, schizophrenic patients are given a single oral dose of amphetamine. Patients are "protected" from possible exacerbation of their psychosis by ongoing treatment with haloperidol. We hypothesize that the deficit symptoms of schizophrenia may be a reflection of cortical dopaminergic failure. Since cortical dopamine receptors are mostly of the D1 subtype and mesolimbic dopaminergic neurones are of the D2 subtype, we hypothesize that amphetamine, a non-specific dopamine indirector agonist given to a person taking the relatively specific D2 blocking agent haloperidol might enhance D1 function. Six of 21 patients were found to be better on the amphetamine day compared to the placebo day. These six had in common greater ventricular to brain ratio and greater enhancement of blink rate compared to the non responsive group. Studies with chronic administration are in progress.